HPV vaccination: Status quo and emerging concepts;Impfung gegen HPV: Aktueller stand und neue perspektiven zur vakzinierung gegen humanpathogene papillomviren

Gynakologe

Volumn 36, Issue 4, 2003, Pages 313-322

  Grubert, Thomas A ^a,b   Friese, K ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cervical cancer; HPV; Prevention; Vaccine

Indexed keywords

VIRUS ANTIBODY; VIRUS VACCINE; VIRUS VECTOR;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; CLINICAL TRIAL; CONCEPT FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HISTORY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL LITERATURE; MULTICENTER STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TREATMENT OUTCOME; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; VACCINATION; VIRUS CAPSID; VIRUS INFECTION; VIRUS RECOMBINANT; WART VIRUS;

EID: 0038625091     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00129-003-1352-3     Document Type: Article

References (39)

1. Rigoni-Stern D (1842) Fatti statistici relativi alle malattie cancerose. Giornale per servire al progressi della patologia e della terapeutica 2: 507-517
2. zur-Hausen H (1975) Oncogenic herpes viruses. Biochim Biophys Acta 417: 25-53
3. Strauss MJ, Shaw EW, Bunting H, Melnick JL (1949) "Crystalline" virus-like particles from skin papillomas characterized by intranuclear inclusion bodies. Proc Soc Exp Biol Med 72: 46
4. Ayre JE (1949) The vaginal smear: 'precancer' cell studies using a modified technique. Am J Obstet Gynecol 58: 1205-1219
5. Koss LG, Durfee GR (1956) Unusual patterns of squamous epithelium of uterine cervix: cytologic and pathologic study of koilocytotic atypia. Ann NY Acad Sci 63: 1235-1261
6. Meisels A, Fortin R (1976) Condylomatous lesions of the cervix and vagina. I. Cytological patterns. Acta Cytol 20: 505
7. Durst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80: 3812-3815
8. Walboomers JMM, Jacobs MV, Manos MM et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19
9. Münger K (2002) The role of human papillomavirus in human cancers. Front Biosci 7: d641-640
10. Hagensee ME, Olson NH, Baker TS, Galloway DA (1994) Three-dimensional structure of vaccinia virus-produced human papillomavirus type I capsids. J Virol 68: 4503-4505
11. Carter JA, Koutsky LA, Wipf GC et al. (1996) The natural history of HPV 16 capsid antibodies among a cohort of university women. J Inf Dis 174: 927-936
12. Carter JJ (2000) The natural history of HPV 16 IgG and IgA responses and HPV 6 and HPV 18 responses following incident HPV infections, 18th International Papillomavirus Conference, Barcelona
13. Wideroff L, Schiffman MH, Hoover R et al. (1996) Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and -negative women. J Infect Dis 174: 937-943
14. Nasiell K, Roger V, Nasiell M (1986) Behaviour of mild cervical dysplasia during long-term follow up. Obstet Gynecol 67: 665-669
15. Benton C, Shyahidullah H, Hunter JAM (1999) Human papillomaviruses in the immunocompromised. Papillomavirus Report 3: 23-26
16. Maiman M, Fruchter RG, Serur E et al.(1993) Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol 82: 170-174
17. Friese K, Kunz K (1988) HIV-infection and pathology in cervix cytology. Abst. No 622, XII World Congress of Gynecology and Obstetrics, Rio de Janeiro, Brazil
18. Hilders CG, Ras L, van Eendenburg JD, Nooyen Y, Fleuren GJ (1994) Isolation and characterization of tumor-infiltrating lymphocates from cervical carcinoma. Int J Cancer 57: 805-813
19. Evans C, Bauer S, Grubert T et al. (1996) HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother 42: 151-160
20. Nimako M, Fiander AN, Wilkinson GW, Borysiewicz L, Man S (1997) Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.Cancer Res 57: 4855-4861
21. Koutsky LA, Ault KA, Wheeler CM et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645-1651
22. Crum CP (2002) The beginning of the end for cervical cancer? N Engl J Med 347: 1703-1705
23. Da Silva DM, Velders MP, Rudolf MP, Schiller JT, Kast WM (1999) Papillomavirus virus-like particles as anticancer vaccines. Curr Opin Mol Ther 1: 82-88
24. Schäfer K, Müller M, Faath Set al. (1999) Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 81: 881-888
25. Zwaveling S, Mota SCF, Nouta J et al. (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169: 350-358
26. Chen CH, Wang TL, Hung CF et al. (2000) Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042
27. Ji H,Wang TL, Chen CH et al. (1999) Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 10: 2727-2740
28. Tuting T, DeLeo AB, Lotze MT, Storkus WJ (1997) Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 27: 2702-2707
29. Ying H, Zaks TZ, Wang RF et al. (1999) Cancer therapy using a self-replicating RNA vaccine. Nat Med 5: 823-827
30. Borysiewicz LK, Fiander A, Nimako M et al. (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347: 1523-1527
31. He Z, Wlazlo AP, Kowalczyk DW et al. (2000) Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270: 146-161
32. Jabbar IA, Fernando GJ, Saunders N et al. (2000) Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 18: 2444-2453
33. Gunn GR, Zubair A, Peters C et al.(2002) Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167: 6471-6479
34. De Bruijn ML, Schuurhuis DH, Vierboom MP et al. (1998) Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 58: 724-731
35. Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA (1999) Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 59: 1184-1187
36. Hodi FS, Dranoff G (1998) Genetically modified tumor cell vaccines. Surg Oncol Clin N Am 7: 471-485
37. Bubenik J, Simova J, Hajkova R et al. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int J Oncol 14: 593-597
38. Hallez S, Detremmerie O, Giannouli C et al.(1999) Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 81: 428-437
39. Hughes JP, Garnett GP, Koutsky L (2002) The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13:631-639